(Hong Kong, March 5, 2026) – The Hong Kong Science and Technology Parks Corporation (Science Park Corporation) and Cytiva, a global leader in the life sciences field, jointly held the &#34;Cytiva Day&#34; themed event and signed a strategic cooperation agreement to promote Hong Kong's position as an international biotechnology hub.
The &#34;Cytiva Day&#34; themed &#34;Research-Driven, Transformative Breakthrough&#34; gathered industry experts, researchers, business leaders, and representatives from startup teams through thematic forums, technical explanations, and industry-academia-research matchmaking sessions to discuss industry trends and witness a milestone in cooperation. The signing of the strategic cooperation agreement marks the beginning of a partnership to promote the transformation of the biotechnology and pharmaceutical industry in Hong Kong, talent training, and industrial capacity building.
Cytiva Day's Four Key Segments Focus on Building a Communication Platform for the Biopharmaceutical Industry
As an annual brand event for Cytiva's deep engagement in the Hong Kong market, this year's Cytiva Day revolves around four main themes: &#34;Academia, Technology, Industry, and Cooperation,&#34; carefully planning core segments to create a high-standard cross-industry communication platform. This includes a cutting-edge technology thematic forum closely aligned with the Hong Kong SAR government's direction in promoting new industrialization and life and health technology, providing over a hundred industry professionals present with forward-looking and practical industry insights.
Representatives from Cytiva and the Science Park Corporation officially signed the strategic cooperation agreement in front of all guests, committing to deep cooperation in key areas such as industry-academia-research transformation support, professional talent training, and innovation capability building. This signing marks the further establishment of an international life sciences leader using Hong Kong as a regional strategic base, in conjunction with the Science Park Corporation's pivotal role in the innovation and technology ecosystem, to jointly promote the advancement of Hong Kong's biopharmaceutical industry chain towards high-end and large-scale development, injecting new momentum into the biopharmaceutical development of the Greater Bay Area and the Asia-Pacific region.
Cytiva's China President Li Lei stated, &#34;The rapid development of new therapies demands higher quality talent. We will introduce a globally standardized technical training system to Hong Kong to help build a sustainable talent pipeline, providing core human resource support for industrial upgrading.&#34;
Hong Kong Science and Technology Parks Corporation CEO Wong Ping-sze emphasized in his speech, &#34;Professional consulting services will effectively bridge basic research and industrial applications, assisting local enterprises in overcoming technical bottlenecks. The Science Park Corporation currently gathers over 300 life and health technology companies, dedicated to building a comprehensive life and health technology ecosystem and enhancing Hong Kong's international influence in related fields.&#34;
This collaboration between Cytiva and the Science Park Corporation coincides with a critical period for Hong Kong in advancing the &#34;Priority Review&#34; system for medical products and establishing an internationally recognized regulatory system for medical products. The two parties will inject new momentum into the industry from three aspects: talent, technology, and platforms, accelerating the internationalization and high-end development of Hong Kong's biopharmaceutical industry.
Looking ahead, both parties will also engage in deeper cooperation in areas such as setting industry standards, international technical exchanges, and innovation project incubation, promoting the integration of Hong Kong's biopharmaceutical industry with the global innovation network, and providing higher quality medical health solutions for patients worldwide. This strategic cooperation marks a new milestone in the construction of Hong Kong's biopharmaceutical industry ecosystem, expected to become a model for collaborative innovation between research institutions and leading enterprises in the industry

LABU

SBIO

The Hong Kong Science and Technology Parks Corporation has signed a strategic cooperation agreement with Cytiva, a global leader in life sciences, to jointly promote Hong Kong as an international biotechnology hub. This collaboration includes hosting a themed event called "Cytiva Day," focusing on research-driven initiatives and the transformation of industry-academia research, as well as establishing a communication platform for the biopharmaceutical industry. Both parties will engage in in-depth cooperation in areas such as talent training and innovation capability building, injecting new momentum into the development of biomedicine in Hong Kong and the Asia-Pacific region

The technology park company partners with global life sciences leader Synthego